A Phase II Evaluation of Gefitinib in the Treatment of Persistent or Recurrent Endometrial Cancer: A Gynecologic Oncology Group Study

BACKGROUND: A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer. METHODS: Women with histologically confirmed persistent/recurrent endometrial cancer were treated with 500 mg oral gefitinib daily until progression o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Leslie, Kimberly K., Sill, Michael W., Fischer, Edgar, Darcy, Kathleen M., Mannel, Robert S., Tewari, Krishnansu S., Hanjani, Parviz, Wilken, Jason A., Baron, Andre T., Godwin, Andrew K., Schilder, Russell J., Singh, Meenakshi, Maihle, Nita J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3700732/
https://ncbi.nlm.nih.gov/pubmed/23438670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2013.02.019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados